Skip to content

Author

V. Viprakasit

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Sep 2026

Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

Findings support mitapivat as the first oral disease-modifying therapy for adults with transfusion-dependent α-thalassaemia or β-thalassaemia, providing a new treatment option to reduce transfusion burden in this patient population.

M. Cappellini, Sujit Sheth, A. Taher et al. · 3 citations
Review Oct 2026

Future-proofing thalassaemia care: harnessing scalable therapies, artificial intelligence, and global collaboration.

The emerging role of repurposed low-cost therapies, particularly hydroxyurea and thalidomide, as disease-modifying options in resource-limited settings are discussed and opportunities to democratise access to curative gene therapies through technological developments, decentralised manufacturing, regional collaboration...

Hanny T. Al-Samkari, F. Aboobacker, B. Andemariam et al. · 2 citations
#gene editing Open access Sep 2026

Human genetics implicates a BACH2-NRF2 axis in fetal haemoglobin activation.

Human genetic studies have identified key regulators of fetal haemoglobin (HbF) expression, including BCL11A, resulting in therapeutic advances1-8. Yet the mechanisms by which HbF expression is activated remain incompletely understood9. Here we conduct a large multi-ancestry genome-wide association study of HbF levels...

Chun-Jie Guo, U. Arora, Xiao-Heng Cheng et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.